APYX MEDICAL CORPORATION TO RELEASE FIRST QUARTER OF FISCAL YEAR 2022 FINANCIAL RESULTS ON MAY 12, 2022By ApyxMedical|2025-12-12T19:19:07+00:00April 4, 2022|2022 Shareholder News, J-Plasma, Renuvion|
APYX MEDICAL CORPORATION ANNOUNCES FDA 510(K) SUBMISSION WITH CLINICAL STUDY SUPPORT FOR THE USE OF THE RENUVION APR HANDPIECE FOR AESTHETIC PROCEDURES TO IMPROVE APPEARANCE OF LAX SKINBy ApyxMedical|2025-12-12T19:19:32+00:00April 4, 2022|2022 Shareholder News, J-Plasma, Renuvion|
APYX MEDICAL CORPORATION REPORTS FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS; INTRODUCES FULL YEAR 2022 FINANCIAL OUTLOOKBy ApyxMedical|2025-12-12T19:20:04+00:00March 17, 2022|2022 Shareholder News, J-Plasma, Renuvion|
APYX MEDICAL CORPORATION NOTIFIED OF PENDING FDA MEDICAL DEVICE SAFETY COMMUNICATION RELATED TO ITS ADVANCED ENERGY PRODUCTSBy ApyxMedical|2025-12-12T19:20:29+00:00March 14, 2022|2022 Shareholder News, J-Plasma, Renuvion|
APYX MEDICAL CORPORATION ANNOUNCES PEER-REVIEWED PUBLICATION FEATURING RESULTS FROM THE U.S. IDE CLINICAL STUDY EVALUATING THE RENUVION DERMAL HANDPIECE USING APYX’S HELIUM PLASMA TECHNOLOGY FOR DERMAL RESURFACING PROCEDURESBy ApyxMedical|2025-12-12T19:27:53+00:00February 17, 2022|2022 Shareholder News, J-Plasma, Renuvion|
APYX MEDICAL CORPORATION TO RELEASE FOURTH QUARTER AND FISCAL YEAR 2021 FINANCIAL RESULTS ON MARCH 17, 2022By ApyxMedical|2025-12-12T19:21:22+00:00January 27, 2022|2022 Shareholder News, J-Plasma, Renuvion|
APYX MEDICAL CORPORATION REPORTS PRELIMINARY FOURTH QUARTER AND FULL YEAR 2021 REVENUE RESULTSBy ApyxMedical|2025-12-12T19:21:47+00:00January 10, 2022|2022 Shareholder News, J-Plasma, Renuvion|
APYX MEDICAL CORPORATION REPORTS THIRD QUARTER 2021 FINANCIAL RESULTS AND UPDATES FULL YEAR 2021 OUTLOOKBy ApyxMedical|2025-12-12T19:22:26+00:00November 11, 2021|2021 Shareholder News, J-Plasma, Renuvion|
APYX MEDICAL CORPORATION TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES IN NOVEMBER AND DECEMBERBy ApyxMedical|2025-12-12T19:29:20+00:00November 10, 2021|2021 Shareholder News, J-Plasma, Renuvion|
APYX MEDICAL CORPORATION TO RELEASE THIRD QUARTER OF FISCAL YEAR 2021 FINANCIAL RESULTS ON NOVEMBER 11, 2021By ApyxMedical|2025-12-12T19:29:47+00:00October 4, 2021|2021 Shareholder News, J-Plasma, Renuvion|
APYX MEDICAL CORPORATION ANNOUNCES APPOINTMENT OF WENDY LEVINE TO THE COMPANY’S BOARD OF DIRECTORSBy ApyxMedical|2025-12-12T19:30:11+00:00August 30, 2021|2021 Shareholder News, J-Plasma, Renuvion|
APYX MEDICAL CORPORATION REPORTS SECOND QUARTER 2021 FINANCIAL RESULTS AND UPDATES FULL YEAR 2021 OUTLOOKBy ApyxMedical|2025-12-12T19:30:49+00:00August 12, 2021|2021 Shareholder News, J-Plasma, Renuvion|
APYX MEDICAL CORPORATION TO RELEASE SECOND QUARTER OF FISCAL YEAR 2021 FINANCIAL RESULTS ON AUGUST 12, 2021By ApyxMedical|2025-12-12T19:31:16+00:00July 12, 2021|2021 Shareholder News, J-Plasma, Renuvion|
APYX MEDICAL CORPORATION TO PARTICIPATE IN THE JMP SECURITIES LIFE SCIENCES CONFERENCEBy ApyxMedical|2025-12-12T19:31:44+00:00June 3, 2021|2021 Shareholder News, J-Plasma, Renuvion|
APYX MEDICAL CORPORATION ANNOUNCES FDA 510(K) SUBMISSION FOR THE USE OF RENUVION IN DERMAL RESURFACING PROCEDURESBy ApyxMedical|2025-12-12T19:32:06+00:00June 1, 2021|2021 Shareholder News, J-Plasma, Renuvion|
APYX MEDICAL CORPORATION REPORTS FIRST QUARTER 2021 FINANCIAL RESULTS AND UPDATES FULL YEAR 2021 OUTLOOKBy ApyxMedical|2025-12-12T19:32:32+00:00May 12, 2021|2021 Shareholder News, J-Plasma, Renuvion|
